National Healthcare Security Administration: 46,000 medical institutions participated in 11 batches of centralized procurement with 77% of the procurement being specific to particular brands.

Regarding the "stability in clinical use" principle of the eleventh batch of centralized procurement, a relevant person from the National Medical Insurance Administration stated that for this round of procurement, medical institutions can either report quantities by generic name as before, or by specific brand. If the brand reported by a medical institution is selected, it will directly become the supplier for that institution, improving the match between clinical demand and supply. The improvement of the reporting rules has received support from a large number of medical institutions and companies. 46,000 medical institutions participated in the reporting for this round of centralized procurement, with 77% reporting by specific brand. The above-mentioned person also stated that 60-80% of the quantities reported by medical institutions are designated as the target for enterprise competition, which is also the agreed procurement quantity for the medical institutions. The remaining portion can still be selected by the medical institutions themselves. For companies with high demand from medical institutions but did not qualify due to pricing, if they accept the selected price, they can "resurrect" and regain their eligibility, better meeting clinical needs.